|
Alex de Winter brings a background in bioscience and technology development to the Mohr Davidow team. He supports the partnership in evaluating investments in the areas of life sciences and personalized medicine, and biotechnology-based cleantech.
Prior to Mohr Davidow, Alex spent two years at Pacific Biosciences in Menlo Park, where he researched single-molecule DNA sequencing, integrating biochemistry, optics, and nanotechnology. Alex has also worked at 454 Life Sciences (acquired by Roche), where he advanced the biochemistry behind the company's GS20, the first of the next-generation DNA sequencing instruments.
Alex received an MBA from the University of California, Berkeley. He also earned a doctorate in Chemistry from Stanford University, where he studied bacterial photosynthesis. He received his B.A. in English and Chemistry magna cum laude from Amherst College.
< Back to Team Main
|
